Although European-American (EA) women, overall, have higher breast cancer incidence than African- American (AA) women, AA women are more likely to be diagnosed at a younger age and to have more aggressive tumors, characterized by higher grade, higher proliferative indices, and lack of expression of estrogen (ER) and progesterone receptors (PR). AA women are also more likely than EAs to have triple- negative breast cancers (TNBCs), which are negative for ER, PR and HER2. These tumors have poor prognosis because they tend to be higher grade and are not responsive to anti-estrogen or anti-HER2 therapy, thus with fewer treatment options available. The reasons for these racial disparities in breast cancer aggressiveness and age at onset are unknown. The Hippo pathway was first identified in Drosophila for its control of organ size by modulating cell growth, proliferation and apoptosis, with all the core components well conserved in mammals. Down-regulation of Hippo pathway components LATS1/2 by DNA hypermethylation has been associated with large tumor size, lymph node metastasis and ER/PR negativity. Our preliminary data also showed that dysfunction of Hippo pathway components YAP/TAZ activates the EGFR signaling and YAP/TAZ is specifically increased in triple-negative and high-grade breast tumors, the subtypes more prevalent among young AA than EA women. Based on the above evidence, we hypothesize that dysfunction of the Hippo signaling pathway leads to aberrant activation of EGFR signaling in the more aggressive breast cancer, which occurs more frequently in AA than EA women. We will investigate this hypothesis in the context of two existing study populations, with the following two specific aims: 1) Determine whether YAP/TAZ-activated EGFR signaling pathway contributes to TNBC tumorigenesis, and 2) Investigate differential EGFR activation by YAP/TAZ between AA and EA women using breast cancer tumor collections. The approach is innovative, because it takes new basic science discoveries to human populations and investigates heretofore unexamined pathways in relation to breast cancer disparities. The proposed research is significant, because it is the first step in a translational continuum of research that is expected to lead to discovery of the role of the Hippo signaling pathway alterations in AA and EA women, as well as associations with aggressive breast cancer. This translational work will ultimately help identify women at a high risk of aggressive breast cancers and discover novel approaches to eliminate breast cancer racial disparities. Our integral approach may also be applied to studying other molecular pathways relevant to health disparities on a broader scale.
The proposed research is relevant to public health because our integrative approach is expected to translate our findings from the bench to patient populations and to reveal the integral role of the Hippo pathway in breast cancer disparities. This translational approach will ultimately help to identify women at a high risk of aggressive breast cancer and the discovery of novel approaches to eliminate breast cancer racial disparities. This translational approach may also be applied to studying other molecular pathways relevant to health disparities on a broader scale.
|Denson, Kayla E; Mussell, Ashley L; Shen, He et al. (2018) The Hippo Signaling Transducer TAZ Regulates Mammary Gland Morphogenesis and Carcinogen-induced Mammary Tumorigenesis. Sci Rep 8:6449|
|Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061|
|Zhang, Yinglong; Shen, He; Withers, Henry G et al. (2017) VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer. Sci Rep 7:6190|
|Mao, Xiaona; Li, Pingping; Wang, Yaochun et al. (2017) CRB3 regulates contact inhibition by activating the Hippo pathway in mammary epithelial cells. Cell Death Dis 8:e2546|
|Liu, Jie; Li, Juan; Li, Pingping et al. (2017) Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway. Sci Rep 7:42125|
|Li, Ying-Wei; Guo, Jin; Shen, He et al. (2016) Phosphorylation of Tyr188 in the WW domain of YAP1 plays an essential role in YAP1-induced cellular transformation. Cell Cycle 15:2497-505|
|Zhang, Jianmin; Yao, Song; Hu, Qiang et al. (2016) Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium. Carcinogenesis 37:951-956|
|Wilson, Kayla E; Yang, Nuo; Mussell, Ashley L et al. (2016) The Regulatory Role of KIBRA and PTPN14 in Hippo Signaling and Beyond. Genes (Basel) 7:|
|Ciamporcero, E; Shen, H; Ramakrishnan, S et al. (2016) YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene 35:1541-53|
|Li, Ying-Wei; Shen, He; Frangou, Costa et al. (2015) Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. Cell Cycle 14:146-56|
Showing the most recent 10 out of 13 publications